Ann: Entitlement Offer Prospectus & Appendix 3B , page-2

re: Ann: Entitlement Offer Prospectus & Appen... Re: the additional cancer indications, this snippet from the prospectus.

"Based on current CVac data which demonstrate the
immune activity of CVac, the Company believes that
CVac may have beneficial applications for cancer
targets in addition to ovarian cancer. The Company
plans for the initiation of pilot (phase 2) clinical trials
of CVac for additional mucin 1 over-expressing
cancer targets.

The Company has received a grant from the Saxony
development bank in Germany to co-fund these
phase 2 trials in additional cancer targets. It is
expected that this grant would cover approximately
50% of the total costs of the trial with the Company
funding the remaining part of the program.

The Company plans to finalise plans and announce
details of the new trials in the 2nd quarter of the 2013
calendar year"


So, still on target to announce the new indications within the next 6 weeks, and 50% of the trial costs are covered by the Saxony grant.